Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 vaccination response in people living with HIV
NL-OMON52193Recruiting
- Sponsor
- OLVG
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Open-label trial of tozinameran, elasomeran, ChAdOx1 nCoV-19 and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by OLVG. Primary endpoints: Antibody response after completed mRNA primary vaccination, Response after additional Moderna vaccination in hyporesponders and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52193.